CROs speed up drug development. Biointron demonstrates how its expertise in antibody discovery, expression, and characterization helps partners achieve faster results.
Single B cell technology accelerates antibody discovery. Biointron demonstrates how this approach delivers potent candidates faster and with greater precision.
Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects
The nucleocapsid of a virus, which consists of the capsid enclosing the viral nucleic acid, can be a target for antibody therapies. When a virus infects a host, its nucleocapsid becomes exposed to the immune system, triggering the production of antibodies specific to proteins present on the nucleocapsid's surface, preventing the virus from entering host cells, disrupting its replication cycle, or marking it for destruction by other components of the immune system.
In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.
Agonist antibodies activate receptors to modulate biology. Biointron explores their mechanisms, therapeutic promise, and applications in immune regulation and oncology.
Toxins are substances produced by living organisms, such as bacteria, fungi, plants, and animals, that are harmful to other organisms. Antibodies play a crucial role in immune responses for the body's defense against toxin intoxication, in addition to being invaluable tools for both diagnostic and therapeutic applications.
Recombinant antibody production ensures reproducibility and accuracy. Biointron provides reliable expression and purification to create research tools that advance discovery.
CHO cell line development is central to therapeutic antibody production. Biointron optimizes expression systems to deliver scalable, reliable, and high-yield solutions.
Therapeutic antibody discovery begins with screening. Biointron applies ELISA, SPR, and AI-driven tools to identify high-affinity antibodies with precision and speed.
Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.
Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, which can cause bone damage, anemia, kidney dysfunction, and weakened immunity. Despite being incurable, advances in antibody therapies have shown significant progress in the management of the disease, highlighting the ongoing efforts in the development of more effective treatments.
VHH antibodies offer stability, small size, and unique binding advantages. Biointron highlights their history, applications, and growing role in research and therapeutics.
Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.
You can also contact us on the Scientist and Science Exchange marketplaces.
